Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milciclib in Thymic Carcinoma
NCT01011439Phase 2Terminated
- Sponsor
- Tiziana Life Sciences
- Start
- Feb 2010
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of milciclib in thymic carcinoma (TC) and Thymoma type B3 (B3), sponsored by Tiziana Life Sciences. Primary endpoint: Progression-free Survival Rate at 3 Months. Started Feb 2010; status: terminated.
02
Drugs
milciclib
03
Conditions
thymic carcinoma (TC)Thymoma type B3 (B3)
Beyond the preview
Go deeper on NCT01011439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01011439.